Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
Innovent Biologics (IVBIY) secures second Chinese approval for lung cancer therapy Dovbleron developed with U.S. biotech ...
Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Innovent Biologics (IVBIY) collaborates with Roche (RHHBY) to develop the antibody-drug conjugate IBI3009 for small cell lung ...
Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising ...
Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.
Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...
Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...